Matrix metalloproteinases in neuroinflammation

GLIA

Volumn 39, Issue 3, 2002, Pages 279-291

  Rosenberg, Gary A ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Matrix metalloproteinases; Neuroinflammation; TIMPs

Indexed keywords

MATRIX METALLOPROTEINASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; BRAIN ISCHEMIA; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYMOLOGY; HUMAN; INFLAMMATION; NERVE CELL; PATHOLOGY;

ANIMALS; BRAIN ISCHEMIA; ENZYME ACTIVATION; ENZYME INDUCTION; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; NEURONS;

EID: 0036737795     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10108     Document Type: Article

References (94)

1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. 1997. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406-415.
2. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH, Banda MJ. 1990. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50:2322-2329.
3. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. 2000. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1689.
4. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH. 2001. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732.
5. Baker AH, Zaltsman AB, George SJ, Newby AC. 1998. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101:1478-1487.
6. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. 1995. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47:1039-1047.
7. Bian J, Jacobs C, Wang Y, Sun Y. 1996. Characterization of a putative p53 binding site in the promoter of the mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene. Carcinogenesis 17:2559-2562.
8. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283.
9. Brown PD. 1998. Synthetic inhibitors of matrix metalloproteinases. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. San Diego, CA: Academic Press. p 243-262.
10. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. 1997. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17:439-444.
11. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJ, Miller KM. 1997. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74:85-94.
12. Colbourne F, Sutherland GR, Auer RN. 1999. Electron microscopic evidence against apoptosis as the mechanism of neuronal death in global ischemia. J Neurosci 19:4200-4210.
13. Colton CA, Keri JE, Chen WT, Monsky WL. 1993. Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J Neurosci Res 35:297-304.
14. Cuzner ML, Opdenakker G. 1999. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94:1-14.
15. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J. 1996. The expression of tissue-type plaminogen activator, matrix metalloproteases and endogenous inhibitor in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55:1194-1209.
16. Deb S, Gottschall PE. 1996. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta- amyloid peptides. J Neurochem 66:1641-1647.
17. Du C, Hu R, Csernansky CA, Hsu CY, Choi DW. 1996. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis? J Cereb Blood Flow Metab 16:195-201.
18. Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T, Hyman BT, Moskowitz MA. 1998. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 18:238-247.
19. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A.2001. Matrix metalloproteinases (MMPs) and their tissue inhibitor (TIMPs) as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol 50:443-451.
20. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH. 1999. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 19:1020-1028.
21. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. 2001a. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393-1400.
22. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. 2001b. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393-1400.
23. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al. 1994. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370:555-557.
24. Gijbels K, Masure S, Carton H, Opdenakker G. 1992. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41:29-34.
25. Gijbels K, Galardy RE, Steinman L. 1994. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-2182.
26. Gottschall PE, Yu X. 1995. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 64:1513-1520.
27. Graham SH, Chen J. 2001. Programmed cell death in cerebral ischemia. J Cereb Blood Flow Metab 21:99-109.
28. Guedez L, Courtemanch L, Stetler-Stevenson M. 1998. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 92:1342-1349.
29. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. 1995. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120-2126.
30. Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN. 2000. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123:698-709.
31. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. 1999. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624-633.
32. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. 1986a. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 261:2814-2818.
33. Herron GS, Werb Z, Dwyer K, Banda MJ. 1986b. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 261:2810-2813.
34. Hewson AK, Smith T, Leonard JP, Cuzner ML. 1995. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 44:345-349.
35. Hughes PM, Wells GM, Clements JM, Gearing AJ, Redford EJ, Davies M, Smith KJ, Hughes RA, Brown MC, Miller KM. 1998. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 121:481-494.
36. Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257.
37. Kleiner DE, Stetler-Stevenson WG. 1994. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218:325-329.
38. Kuroiwa T, Ting P, Martinez H, Klatzo I. 1985. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol (Berl) 68:122-129.
39. La Fleur M, Underwood JL, Rappolee DA, Werb Z. 1996. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J Exp Med 184:2311-2326.
40. Lapchak PA, Chapman DF, Zivin JA. 2000. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31:3034-3040.
41. Lassmann H, Zimprich F, Vass K, Hickey WF. 1991. Microglial cells are a component of the perivascular glia limitans. J Neurosci Res 28:236-243.
42. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. 1994. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269:9352-9360.
43. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. 1999. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122:191-197.
44. Leib SL, Leppert D, Clements J, Tauber MG. 2000. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 68:615-620.
45. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, Tauber MG, Leppert D. 2001. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124:1734-1742.
46. Lemons ML, Sandy JD, Anderson DK, Howland DR. 2001. Intact aggrecan and fragments generated by both aggrecans and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury. J Neurosci 21:4772-4781.
47. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. 1995. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154:4379-4389.
48. Leppert D, Hughes P, Huber S, Erne B, Grygar C, Said G, Miller KM, Steck AJ, Probst A, Fuhr P. 1999. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy Neurology 53:62-70.
49. Liedtke W, Cannella B, Mazzaccaro RJ, Clements JM, Miller KM, Wucherpfennig KW, Gearing AJ, Raine CS. 1998. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 44:35-46.
50. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68.
51. Loging WT, Reisman D. 1999. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 18:7608-7615.
52. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. 1999. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 19:267-284.
53. Maeda A, Sobel RA. 1996. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55:300-309.
54. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332.
55. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, et al. 1994. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 370:558-561.
56. Mignatti P, Rifkin DB. 1996. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117-137.
57. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. 2001a. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759-1766.
58. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J. 2001b. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762-2767.
59. Mun-Bryce S, Rosenberg GA. 1998a. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 274:R1203-11.
60. Mun-Bryce S, Rosenberg GA. 1998b. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163-1172.
61. Mun-Bryce S, Lukes A, Wallace J, Lukes-Marx M, Rosenberg GA. 2002. Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation. Brain Res 933:42-49.
62. Nagase H. 1997. Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160.
63. Nagase H, Woessner JF Jr. 1999. Matrix metalloproteinases. J Biol Chem 274:21491-21494.
64. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. 2000. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149.
65. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. 1999. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464-8475.
66. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. 1992. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem 267:17321-17326.
67. Perry VH, Andersson PB. 1992. The inflammatory response in the CNS. Neuropathol Appl Neurobiol 18:454-459.
68. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley, JP. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076.
69. Redford EJ, Smith KJ, Gregson NA, Davies M, Hughes P, Gearing AJ, Miller K, Hughes RA. 1997. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 120:1895-1905.
70. Romanic AM, Madri JA. 1994. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 4:145-156.
71. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. 1998. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020-1030.
72. Rosenberg GA. 1995. Matrix metalloproteinases in brain injury. J Neurotrauma 12:833-842.
73. Rosenberg GA. 2001. Matrix metalloproteinases in multiple sclerosis: Is it time for a treatment trial? Ann Neurol 50:431-433.
74. Rosenberg GA, Navratil M. 1997. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 48:921-926.
75. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. 1992. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576:203-207.
76. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. 1995. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703:151-155.
77. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. 1996a. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46:1626-1632.
78. Rosenberg GA, Navratil M, Barone F, Feuerstein G. 1996b. Proteolyric cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360-366.
79. Rosenberg GA, Estrada EY, Dencoff JE. 1998. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189-2195.
80. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A. 2001a. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893:104-112.
81. Rosenberg GA, Sullivan N, Esiri MM. 2001b. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 32:1162-1168.
82. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM. 1997. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 138:4902-4911.
83. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. 1994. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65.
84. Schlondorff J, Blobel CP. 1999. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 112:3603-3617.
85. Smith MR, Kung H, Durum SK, Colburn NH, Sun Y. 1997. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 9:770-780.
86. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. 1995. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331-5338.
87. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P. 1999. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53:1402-1408.
88. Van Wart HE, Birkedal Hansen H. 1990. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 87:5578-5582.
89. Vos CM, Sjulson L, Nath A, McArthur JC, Pardo CA, Rothstein J, Conant K. 2000. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol 163:324-330.
90. Wang X, Barone FC, White RF, Feuersteln GZ. 1998. Subtractive cloning identifies tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) increased gene expression following focal stroke. Stroke 29:516-520.
91. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K. 1999. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53:1397-1401.
92. Wells GM, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM, Clements JM. 1996. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard. Glia 18:332-340.
93. Yong VW, Kerkoski CA, Forsyth PA, Bell R, Edwards DR. 1998. Matrix metalloproteinases and diseases of the CNSs. TINS 21:75-80.
94. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.